Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pluristem Therapeutics is set to construct a new manufacturing plant in Hafia, under an agreement signed with MTM - Scientific Industries Center Haifa.
Subscribe to our email newsletter
In the new plant, the company intends to manufacture PLX (PLacental eXpanded) cell product candidates which is indicated as a treatment for critical limb ischemia (CLI), adjuvant hip replacement surgery, intermittent claudication (IC), pulmonary hypertension (PH), muscle injuries, and other diseases.
The new plant is expected to have the capacity to produce PLX cells for 150,000 patients in a year.
Pluristem expects that its new regenerative medicine facility will meet both European Medicines Agency (EMA) and US Food and Drug Administration (FDA) regulatory requirements, as well as the standards outlined by the Israeli Ministry of Health.
Pluristem chairman and CEO Zami Aberman said the new manufacturing site will implement their industry experience and support Pluristem’s strategy for potentially treating millions of patients with life threatening diseases.